Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients

International Journal of Drug Policy

Volumn 42, Issue , 2017, Pages 30-35

  Lucas, Philippe ^a,b,c   Walsh, Zach ^d  

^a Tilray   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Addiction; Cannabis; Marijuana; Mental health; Opioids; Pain; Substitution

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CODEINE; HYDROMORPHONE; ILLICIT DRUG; MEDICAL CANNABIS; MORPHINE; OPIATE DERIVATIVE; OXYCODONE PLUS PARACETAMOL; PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC PAIN; DEMOGRAPHY; DEPRESSION; DRUG SUBSTITUTION; DRUG USE; FEMALE; HEADACHE; HEALTH SURVEY; HUMAN; INSOMNIA; LOSS OF APPETITE; MALE; MENTAL HEALTH; NAUSEA; SELF REPORT; SMOKING; STRESS; ECONOMICS; LICENSING; MIDDLE AGED; PRESCRIPTION; QUESTIONNAIRE; SUPPLY AND DISTRIBUTION;

ADULT; AGED; ANALGESICS, OPIOID; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LICENSURE; MALE; MEDICAL MARIJUANA; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES;

EID: 85011883586     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.01.011     Document Type: Article

References (29)

1. Allsop, D.J., Dunlop, A.J., Saddler, C., Rivas, G.R., McGregor, I.S., Copeland, J., Changes in cigarette and alcohol use during cannabis abstinence. Drug and Alcohol Dependence 138:1 (2014), 54–60, 10.1016/j.drugalcdep.2014.01.022.
2. Bachhuber, M.A., Salone, B., Cunningham, C.O., Barry, C.L., Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010. JAMA Internal Medicine 4 (2014), 1–6, 10.1001/jamainternmed.2014.4005.
3. Belle-Isle, L., Walsh, Z., Callaway, R., Lucas, P., Capler, R., Kay, R., Holtzman, S., Barriers to access for Canadians who use cannabis for therapeutic purposes. International Journal of Drug Policy 25:4 (2014), 691–699, 10.1016/j.drugpo.2014.02.009.
4. Blessing, E.M., Steenkamp, M.M., Manzanares, J., Marmar, C.R., Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:4 (2015), 825–836, 10.1007/s13311-015-0387-1.
5. Bonn-Miller, M.O., Boden, M.T., Bucossi, M.M., Babson, K.A., Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. The American Journal of Drug and Alcohol Abuse 40:1 (2014), 23–30, 10.3109/00952990.2013.821477.
6. Bradford, A.C., Bradford, W.D., Medical marijuana laws reduce prescription medication use in medicare part D. Health Affairs 35:7 (2016), 1230–1236, 10.1377/hlthaff.2015.1661.
7. Brown, M.T., Bussell, J.K., Medication adherence: WHO cares?. Mayo Clinic Proceedings 86:4 (2011), 304–314, 10.4065/mcp.2010.0575.
8. Carter, G.T., Weydt, P., Kyashna-Tocha, M., Abrams, D.I., Medicinal cannabis: Rational guidelines for dosing. IDrugs: The Investigational Drugs Journal 7:5 (2004), 464–470 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15154108.
9. Clark, C., The state of play. International Journal of Play, 2013, 1–14, 10.1080/21594937.2013.853462.
10. Eysenbach, G., Improving the quality of web surveys: The checklist for reporting results of internet e-surveys (CHERRIES). Journal of Medical Internet Research, 6(3), 2004, e34+, 10.2196/jmir.6.3.e34.
11. Fischer, B., Murphy, Y., Kurdyak, P., Goldner, E., Rehm, J., Medical marijuana programs—Why might they matter for public health and why should we better understand their impacts?. PMEDR 2 (2015), 53–56, 10.1016/j.pmedr.2014.12.006.
12. Fischer, B., Rehm, J., Goldman, B., Popova, S., Non-medical use of prescription opioids and public health in Canada: An urgent call for research and interventions development. Canadian Journal of Public Health 99:3 (2008), 182–184 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18615937.
13. Hager, M., Among veterans, opioid prescription requests down in step with rise in medical pot. 2016, Globe and Mail Retrieved from http://www.theglobeandmail.com/news/national/among-veterans-opioid-prescription-requests-down-in-step-with-rise-in-medical-pot/article30285591/.
14. Hazekamp, A., Ware, M.A., Muller-Vahl, K., Abrams, D., Grotenhermen, F., The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms. Journal of Psychoactive Drugs 45:3 (2013), 199–210, 10.1080/02791072.2013.805976.
15. Ingersoll, K.S., Cohen, J., The impact of medication regimen factors on adherence to chronic treatment: A review of literature. Journal of Behavioral Medicine 31:3 (2008), 213–224, 10.1007/s10865-007-9147-y.
16. Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A.,.. Díaz, Á., Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology 103 (2015), 16–26, 10.1016/j.neuropharm.2015.12.017.
17. Lucas, P., Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. Journal of Psychoactive Drugs 44:2 (2012), 125–133, 10.1080/02791072.2012.684624.
18. Lucas, P., It can't hurt to ask: A patient-centered quality of service assessment of health Canada's medical cannabis policy and program. Harm Reduction Journal, 9(1), 2012, 2, 10.1186/1477-7517-9-2.
19. Lucas, P., Reiman, A., Earleywine, M., McGowan, S.K., Oleson, M., Coward, M.P., Thomas, B., Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research & Theory 21:5 (2013), 435–442, 10.3109/16066359.2012.733465.
20. Lucas, P., Walsh, Z., Crosby, K., Callaway, R., Belle-Isle, L., Kay, R.,.. Holtzman, S., Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review 35:3 (2016), 326–333, 10.1111/dar.12323.
21. Office of Medical Cannabis, MMPR market statistics, January–May. 2016, Office of Medical Cannabis, Ottawa, 2016.
22. Ogborne, A.C., Smart, R.G., Weber, T., Birchmore-Timney, C., Who is using cannabis as a medicine and why: An exploratory study. Journal of Psychoactive Drugs 32:4 (2000), 435–443, 10.1080/02791072.2000.10400245.
23. Reiman, A., Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal, 6, 2009, 35, 10.1186/1477-7517-6-35.
24. Sawler, J., Stout, J.M., Gardner, K.M., Hudson, D., Vidmar, J., Butler, L.,.. Cockerham, C., The genetic structure of marijuana and hemp. PLoS One, 10(8), 2015, e0133292, 10.1371/journal.pone.0133292.
25. Sylvestre, D.L., Clements, B.J., Malibu, Y., Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology & Hepatology 18:10 (2006), 1057–1063, 10.1097/01.meg.0000216934.22114.51.
26. Walsh, Z., Callaway, R., Belle-Isle, L., Capler, R., Kay, R., Lucas, P., Holtzman, S., Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. International Journal of Drug Policy 24:6 (2013), 511–516, 10.1016/j.drugpo.2013.08.010.
27. Walsh, Z., Gonzalez, R., Crosby, K., Thiessen, M., Carroll, C., Bonn-Miller, M.O., Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 2016, 15–29, 10.1016/j.cpr.2016.10.002.
28. Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T.,.. Collet, J.P., Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Cmaj 182:14 (2010), 1–8, 10.1503/cmaj.091414.
29. Ware, M.A., Wang, T., Shapiro, S., Collet, J.-P., Cannabis for the management of pain: Assessment of safety study (COMPASS). The Journal of Pain, 2015, 1233–1242, 10.1016/j.jpain.2015.07.014.